Despite the huge amount of clinical trials targeting the pathway in cancer, the only approved drug is Everolimus, an mTOR inhibitor, in combination with Exemestane for advanced hormone receptor positive (HR+)/HER2-negative (HER2−) breast cancer that progressed on endocrine therapy14, 15. The gene discussed is ERBB2; the disease is breast cancer.